Llerena S, Cabezas J, Cuadrado A, Olmos JM, González M, García F, Cobo C, Crespo J

Idioma: Ingles.
Referencias bibliográficas: 8
Paginas: 236-239
Archivo PDF: 127.72 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66: 153-94. DOI: 10.1016/ j.jhep.2016.09.001.

2. Lawitz E, Poordad F, Gutierrez JA, Wells JT, Landaverde CE, Evans B, Howe A, et al. Short-duration treatment with elbasvir/ grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology 2017; 65: 439-50.DOI: 10.1002/ hep.28877

3. De Ledinghen V, Leforest C, Hezode C, Pol S, Renault A, Alric L, Larrey DG, et al. Retreatment with Sofosbuvir + Grazoprevir + Elbasvir + Ribavirin of Patients with Hepatitis C Virus Genotype 1 or 4 with RASs at Failure of a Sofosbuvir + Ledipasvir or + Declatasvir or + Simeprevir Regimen. American Association for the Study of Liver Diseases (AASLD); 2016.

4. Foster GR, Agarwal K, Cramp M, Moreea S, Barclay S, Collier J, Brown AS, et al. Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: The C-ISLE Study. Vol. 64. The Liver Meeting Boston: 2016; Abstract Supplement. AASLD 2016, p. 39A.

5. Bourlière M, Gordon SC, Ramji A, Ravendhran N, Tran TT, Hyland RH, ZHang J, et al. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor experienced patients with genotype 1-6 infection: The phase 3 POLARIS-1 study [Abstract 194]. Vol 64. 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2016, p. 102A.

6. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, et al. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology 2016; 151: 651-9 e1.DOI: 10.1053/j.gastro.2016.07.020

7. Serfaty L, Pianko S, Ben-Ari Z, Laursen AL, Hansen J, Gane EJ, Huang H, et al. High SVR rates in patients with chronic HCV GT1, 2 or 3 infection following 16 weeks of MK-3682/ grazoprevir/MK-8408 plus ribavirin after failure of 8 weeks of therapy (Part C of C-CREST-1 & 2) Vol 64. Abstract 112. American Association for the Study of Liver Disease (AASLD); 2016, p. 61A

8. Palladino C, Sanchez-Carrillo M, Mate-Cano I, Vazquez-Moron S, Jimenez-Sousa MA, Gutierrez-Rivas M, Resino S, et al. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep 2017; 7: 2892.DOI: 10.1038/s41598-017-02968-7